Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy

NCT02500199 is registered in ClinicalTrials.gov with Hengrui Therapeutics, Inc. as lead sponsor.

NCT NCT02500199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02500199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy
Lead sponsor
Hengrui Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
June 30, 2015
Completion date
June 30, 2021
Enrollment
50 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric cancer, nsclc, solid tumors